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Although GH treatment for short stature in Turner syndrome
is an accepted treatment in many countries, which GH dosage
to use and which age to start puberty induction are issues of
debate. This study shows final height (FH) in 60 girls with
Turner syndrome treated in a randomized dose-response
trial, combining GH treatment with low dose estrogens at a
relatively young age.
Girls were randomly assigned to group A (4 IU/m2d;0.045
mg/kg/d), group B (first year, 4 IU/m2d; thereafter 6 IU/m2d),
or group C (first year, 4 IU/m2d; second year, 6 IU/m2d; there-
after, 8 IU/m2d). After a minimum of 4 yr of GH treatment, at
a mean age of 12.7  0.7 yr, low dose micronized 17-estradiol
was given orally. After a mean duration of GH treatment of
8.6 1.9 yr, FH was reached at a mean age of 15.8 0.9 yr. FH,
expressed in centimeters or SD score, was 157.6 6.5 or1.6
1.0 in group A, 162.9 6.1 or0.7 1.0 in group B, and 163.6
6.0 or –0.6  1.0 in group C. The difference in FH in centime-
ters, corrected for height SD score and age at start of treat-
ment, was significant between groups A and B [regression
coefficient, 4.1; 95% confidence interval (CI), 1.4, 6.9; P < 0.01],
and groups A and C (coefficient, 5.0; 95% CI, 2.3, 7.7; P < 0.001),
but not between groups B and C (coefficient, 0.9; 95% CI,1.8,
3.6). Fifty of the 60 girls (83%) had reached a normal FH (FH
SD score, more than2). After starting estrogen treatment, the
decrease in height velocity (HV) changed significantly to a
stable HV, without affecting bone maturation (change in bone
age/change in chronological age). The following variables con-
tributed significantly to predicting FH SD score: GH dose,
height SD score (ref. normal girls), chronological age at start
of treatment, and HV in the first year of GH treatment. GH
treatment was well tolerated.
In conclusion, GH treatment leads to a normalization of FH
in most girls, even when puberty is induced at a normal pu-
bertal age. The optimal GH dosage depends on height and age
at the start of treatment and first year HV. (J Clin Endocrinol
Metab 88: 1119–1125, 2003)
THE MOST COMMON clinical characteristic of Turner syn-drome (TS) is short stature. The reason for the short stat-
ure is still under investigation. A recent study has shown that
the etiology of the growth retardation possibly lies in the hap-
loinsufficiency of the SHOX gene (1). Although girls with TS are
not GH deficient (2), subnormal levels of GH and IGF-I have
been reported (3, 4). It has been postulated that a diminished
sensitivity for growth factors might explain their growth retar-
dation (5, 6). Nevertheless, GH treatment in a supraphysiologi-
cal dosage has been shown to accelerate growth (4, 7). Another
clinical feature in most girls with TS is the absence of sponta-
neous pubertal development, for which estrogen substitution is
necessary. Although GH treatment for short stature in TS is now
an accepted treatment in many countries, reports on final height
are inconsistent (8, 9), and which dosage to use and which age
to start puberty induction are issues of debate.
Previously, we have demonstrated that long-term GH treat-
ment in TS leads to normalization of height (4, 10). This study
shows final height (FH) results in 60 girls with TS treated in a
randomized dose-response trial comparing 3 dosage schedules.
In addition, we show the effect of low dose estrogen treatment
begun at a relatively young age. Thereby, we have constructed
a prediction model for FH sd score to aid individual treatment.
Subjects and Methods
Study subjects
Sixty-eight previously untreated girls with TS were enrolled from 8
academic and 3 major nonacademic pediatric departments in The Neth-
Abbreviations: BA, Bone age; CA, chronological age; CI, confidence
interval; FH, final height; HV, height velocity; mPAH, modified pro-
jected adult height; TH, target height; TS, Turner syndrome.
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erlands in an open randomized multicenter GH dose-response study. Six
girls dropped out of the study because of noncompliance and were lost
to follow-up. Two girls were still being treated with GH at the time of
analysis (January 24, 2002) and had not yet reached FH, leaving 60 girls
for analysis of FH in this study (Fig. 1). As the 8 girls not used in the
analysis (either lost to follow-up or had not yet reached FH) were
normally distributed over the randomization groups (4/3/1), and the
baseline clinical data showed no significant difference compared with
the 60 girls with FH, selection bias was unlikely.
The diagnosis was confirmed by lymphocyte chromosomal analysis.
Three of the 68 girls had a prenatal diagnosis. Inclusion criteria were
chronological age (CA) between 2–11 yr, height below the 50th percentile
for healthy Dutch girls (11), and normal thyroid function. Exclusion
criteria were associated endocrine and/or metabolic disorders, growth
failure caused by other disorders or emotional deprivation, hydroceph-
alus, previous use of drugs that could interfere with GH treatment, and
spontaneous puberty (12). Written informed consent was obtained from
the girls and their parents or guardians. The study protocol was ap-
proved by the ethics committee of each participating center.
Study design
At start of the study a total of 15 patients/dosage group was calcu-
lated to be necessary to discover a true mean difference in height velocity
(HV) of 1.0 cm/yr between dosage groups after 2 treatment yr with a
probability of 80% (based on a two-sided t test for paired observations).
Based on this calculation, 68 girls were included from November 1989
until October 1990 in the study to evaluate the effect of augmentation
of GH dosage on HV and FH. Sixty-eight girls were randomly assigned
to 3 groups in blocks of 2, 4, or 6 (randomly chosen) in 4 strata defined
by age and height sd score at the start of treatment. The sequence was
concealed in envelopes until treatment was assigned. The treatment
regiments were: group A (n  23), 4 IU/m2 body surfaced (0.045
mg/kgd); group B (n  23), 4 IU/m2d in the first year, followed by 6
IU/m2d (0.0675 mg/kgd); and group C (n 22), 4 IU/m2d in the first
year, 6 IU/m2d in the second year, and thereafter 8 IU/m2d (0.090
mg/kgd).
Biosynthetic human GH (Norditropin, Novo Nordisk A/S, Bags-
vaerd, Denmark) was given sc once daily at bedtime using a pen in-
jection system. Every 3 months the total GH dose was adjusted to the
calculated body surface. According to the study protocol, the GH treat-
ment was discontinued when HV was less than 1 cm over 6 months or
on the decision of the patient due to satisfaction with achieved height.
In the first 4 yr of GH treatment, no estrogen for pubertal induction was
given to the girls. After 4 yr of GH treatment, estrogen treatment was
started at the yearly visit after the subject had reached the age of 12 yr.
In the girls who became 12 yr old during the first 4 yr of GH treatment,
estrogen treatment was started at 4 yr of GH treatment. Five micrograms
of 17-estradiol/kg body weightd (0.05 g ethinyl estradiol/kgd),
orally, were given in the first 2 yr, 7.5 g/kgd in the third year, and 10
g/kgd thereafter (tablets containing 0.1 mg micronized 17-estradiol
were supplied for the study by Novo Nordisk A/S). Cyclic progesterone
therapy (Duphaston, Solvay Pharmaceuticals BV, Weesp, The Nether-
lands; 5 mg/d during the first 14 d of the month) was added after 2 yr
of estrogen therapy. If puberty had developed spontaneously (Tanner
breast stage 2) before the start of estrogen treatment, no exogenous
estrogen was given.
Height was measured in eight academic and three major nonaca-
demic pediatric departments at baseline and subsequently every 3
months in the same department using a Harpenden stadiometer by three
observers (A.v.T., 1989–1995; T.S., 1995–1998; Y.v.P., 1998–2001). The
mean of four measurements was used for analysis. FH was defined as
the most recent available height after discontinuation of GH treatment
(mean sd, 0.5 0.2 yr after discontinuation of GH treatment). Height
was expressed as the sd score using the references for healthy normal
Dutch girls (ref. normal girls) (13) or the references for North European
untreated girls with TS (ref. TS) (14). HV per year was defined as the
increase in height in centimeters per year. The HV sd score was calcu-
lated using reference values for HV in North European untreated girls
with TS (15). Target height (TH) was adapted from Dutch reference data
with addition of 4.5 cm for secular trend: TH 1/2 (HmotherHfather
 13 cm)  4.5 cm (13). TH range was defined as the TH  1.3 sd, and
TH was expressed as the sd score (13, 16). During GH treatment pubertal
stages were assessed according to Tanner (12). Bone age (BA) was
determined by the same three observers according to the Tanner and
Whitehouse radius, ulna, short bones score (17). Bone maturation was
expressed as the ratio of the change in BA to the change in CA (BA/
CA). Adult height without GH treatment was calculated for each girl
with the modified projected adult height method (mPAH), using the
equation of Lyon, adapted to North European untreated girls with TS
(14, 18, 19). To assess the gain in FH, FH was compared with the mPAH
at the start of GH treatment.
Biochemical parameters and hormone assays
Blood samples were taken at the start of the study, subsequently every
year, and 6 months after the discontinuation of GH treatment for de-
termination of the glycosylated hemoglobin, leukocytes, hemoglobin,
creatinine, aspartate aminotransferase, alanine aminotransferate, alka-
line phosphatase, free T4, and TSH levels. Plasma IGF-I levels were
determined at the start of treatment; at 6, 18, 30, and 48 months of
treatment; thereafter every year visit until discontinuation of GH treat-
ment; and 6 months after discontinuation of GH treatment. After cen-
trifugation, all samples were frozen (20 C) until assayed. All mea-
surements of IGF-I were performed in one laboratory by RIA as
described previously (20) and were transformed to sd scores using
reference levels for healthy children determined in the same laboratory
(21).
Statistical analysis
Results are expressed as the mean  sd unless indicated otherwise.
Differences between the dosage groups were tested by linear regression
analysis with the variables age and height sd score (ref. normal girls) at
the start of treatment and two dummy variables for dosage group.
Differences in time between continuous variables were compared by
paired two-sided t test for the whole group unless otherwise specified.
A stepwise forward linear regression analysis was used to construct a
prediction model for FH sd score and gain in height (FH – mPAH in
centimeters). The following potential predictor variables were used: BA,
CA, height sd score (ref. normal girls), and IGF-I sd score at the start of
treatment; GH dosage group; target height sd score; karyotype (45,X or
other); first year increase in alkaline phosphatase and in HV (in centi-FIG. 1. Flow diagram of the progress through the phases of the trial.
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meters); and first 18 months increase in IGF-I sd score. Only the variables
with a P 0.05 were kept in the model. Subsequently, the squares of the
remaining variables were tested for significance, after which the vari-
ables were tested for possible interactions. All correlations were partial
correlations, adjusted for GH dosage. P  0.05 was considered signif-
icant. All calculations were performed using SPSS version 9.0 (SPSS, Inc.,
Chicago, IL).
Results
In Table 1 the pretreatment clinical data of the 60 girls with
FH are shown. Baseline clinical data were similar for the
three GH dosage groups. After a mean duration of GH treat-
ment of 8.6 1.9 yr, FH was reached at a mean age of 15.8
0.9 yr, and with a bone age of 15.5 0.6 yr. Forty-eight of the
60 girls had GH treatment duration of 7 yr or more.
FH was 157.6 6.5 cm in group A, 162.9 6.1 cm in group
B, and 163.6  6.0 cm in group C (Table 2). When translated
to sd score, using references for normal girls, FH was1.6
1.0 cm for group A, 0.7  1.0 cm for group B, and –0.6 
1.0 cm for group C (Fig. 2). The difference in FH (centime-
ters), corrected for height sd score and age at the start of
treatment, was significant between groups A and B [regres-
sion coefficient, 4.1; 95% confidence interval (CI), 1.4, 6.9; P
0.01] and between groups A and C (coefficient 5.0; 95% CI,
2.3, 7.7; P  0.001), but not between groups B and C (coef-
ficient, 0.9; 95% CI, 1.8, 3.6). Fifty of the 60 girls (83%) had
reached a normal FH (FH sd score, more than 2). Thirty-
eight of the 60 girls (63%) reached an FH within their TH
range.
The mean gain in final height (FH  mPAH) in group A
was 11.9  3.6 cm, being significantly lower compared with
15.7  3.5 cm in group B (regression coefficient, 4.2; 95% CI,
1.5, 6.9; P 0.01) and compared with 16.9 5.2 cm in group
C (coefficient, 5.2; 95% CI, 2.6, 7.8; P  0.001), but the height
gain in group B was not significantly different from that in
group C (coefficient, 1.0; 95% CI, 1.6, 3.6; P  0.44; Fig. 3).
Similarly, the mean increase in sd score from start of GH
treatment until FH in groups B and C was significantly
higher compared with that in group A (coefficient, 0.7; 95%
CI: 0.31, 1.11; P  0.001), but the increase in group B was
comparable to group C (coefficient, 0.12; 95% CI, 0.27, 0.5;
P  0.5; Table 2).
Estrogen effect
Estrogen treatment was started at a mean age of 12.7 0.7
yr. Tanner breast stage 2 was reached at a mean age of 12.9
0.6 yr, and stage 4 at a mean age of 14.8  1.1 yr. HV before
and after initiation of estrogen treatment is depicted in Fig. 4A.
To homogenize the group for age, only the girls who started
estrogen treatment at age 12 yr were analyzed (n  47). HV
in the year after initiation of estrogen treatment compared
with the HV in the previous year showed no significant
difference (HV0 yr vs. HV1 yr). The downward trend in HV
before initiation of estrogen treatment, however, changed
significantly to a stabile HV after initiation (HV-1 yr-0 yr vs.
HV0 –1 yr; P  0.05). Bone maturation (BA/CA) in the
year before and in the year after initiation of estrogen
treatment was not significantly different (t 0 vs. t  1 yr;
Fig. 4B). GH dosage, GH duration before start of estrogen,
and height at puberty had no significant effect on the dif-
ferences (between before and after initiation of estrogen) in
HV, in the change in HV, or in bone maturation.
FIG. 2. Height SD score for CA (ref. normal Dutch girls) during
GH treatment for group A (), group B (u), and group C (f),
respectively.
TABLE 1. Mean (SD) baseline clinical data
Group A Group B Group C
No. of girls 19 20 21
Chronological age (yr) 6.5 (1.9) 6.9 (2.3) 6.5 (2.4)




2.9 (0.9) 2.7 (0.9) 2.7 (1.0)
Reference, Turner 0.0 (1.1) 0.3 (0.9) 0.2 (1.1)
Maximal GH response
(ATT) (mU/liter)a
18.5 [4–67] 16.5 [5–74] 21.3 [3–66]
Modified projected adult
height (cm)
145.7 (5.7) 147.2 (4.9) 146.6 (5.6)
Target height (cm) 170.4 (6.6) 171.3 (6.0) 170.5 (5.6)
Karyotype
45,X 16 (84%) 19 (95%) 16 (76%)
Other 3 (16%) 1 (5%) 5 (24%)
ATT, Arginine tolerance test.
a Geometric mean [range].
TABLE 2. Mean (SD) height data of 60 girls with TS after long-term GH treatment
Group A (n  19) Group B (n  20) Group C (n  21)
FH (cm) 157.6 (6.5) [143.1, 172.1] 162.9 (6.1)a [152.4, 176.2] 163.6 (6.0)b [153.3, 172.4]
FH SD score (reference, normal Dutch girls) 1.6 (1.0) [3.8, 0.5] 0.7 (1.0)a [2.6, 1.1] 0.6 (1.0)b [2.1, 0.9]
Height gain (cm) (FH minus mPAH) 11.9 (3.6) [2.8, 17.8] 15.7 (3.5)a [8.1, 20.4] 16.9 (5.2)b [7.2, 28.7]
 Height SD score (from start until FH) 1.2 (0.6) [2, 2.0] 1.9 (0.5)b [0.9, 2.6] 2.1 (0.8)b [0.3, 3.6]
GH duration (yr) 8.9 (1.4) [6.5, 11.1] 8.3 (2.1) [5.5, 12.0] 8.7 (2.0) [5.3, 11.5]
Range is shown in brackets. Linear regression analysis with correction for age and height SD score at start (vs. group A): a P  0.01; b P  0.001.
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Prediction model for FH SD score and gain in height
A stepwise forward linear regression analysis resulted in
a model using the predictor variables GH dose, height sd
score (ref. normal girls) and CA at the start of treatment, and
HV in the first year of GH treatment, accounting for 75.6%
of the variation in FH sd score (residual sd 0.55). Table 3
shows the coefficients of the linear regression model. Vari-
ables, which showed a nonsignificant effect on FH sd score
were IGF-I sd score and BA at the start of treatment, increase
in IGF-I sd score in the first 18 months of treatment, increase
in alkaline phosphatase in the first year of treatment, TH sd
score, and karyotype (45,X, yes or no). The model equation
was: FH sd score2.29 0.80 height sd score at the start
of treatment  0.81  group C (yes  1/no  0)  0.68 
group B (yes  1/no  0)  0.24  HV in the first year of
treatment (cm)  0.087  CA at the start of treatment (yr).
To explore the effect of CA at the start of treatment on FH sd
score, a partial correlation was made, controlling for GH
dosage. The result was a significant negative correlation be-
tween FH sd score and CA (r  0.30; P  0.05).
When using the same predictor variables in a stepwise
forward regression analysis to predict height gain (FH –
mPAH in centimeters), the following model was obtained,
after substitution of HV in the first year of treatment (cen-
timeters) by HV sd score (ref. TS) and age at the start of
treatment, and the addition of GH peak during ATT: height
gain (cm)  10.95 (se, 2.58)  1.15 (0.47)  HV sd score in
the first year of treatment  4.01 (1.18)  froup B (yes/no)
 5.55 (1.16) group C (yes/no) – 1.57 (0.59) height sd score
at the start of treatment – 1.04 (0.28)  CA at the start of
treatment (yr) – 0.083 (0.032)  GH peak (mU/liter). The
model explained 45.6% of the variation in height gain (re-
sidual sd, 3.6 cm).
IGF-I levels
The mean plasma IGF-I sd scores before, during, and 6
months after discontinuation of GH treatment are shown in
Fig. 5. The mean plasma IGF-I sd score increased signifi-
cantly from the start of GH treatment until 7 yr of GH treat-
ment (P  0.0001 for the whole group), from 2.3  1.5 to
1.9  0.8 for group A, from –1.4  1.2 to 2.5  0.9 for group
B, and from –1.9 1.4 to 2.7 0.9 for group C. Although the
increase from the start of treatment until 7 yr of GH treatment
was not significantly different in groups A, B, and C, we did
find a significantly higher IGF-I sd score at 7 yr of GH
treatment in group C compared with group A (P  0.05).
After discontinuation of GH treatment, the IGF-I sd score
decreased significantly (P  0.0001 for the whole group) to
a mean sd score of –0.6  1.0 for group A, 0.1  0.7 for
group B, and –0.1  0.9 for group C; the decrease was not
significantly different between groups. The IGF-I sd score 6
FIG. 3. Height gain (difference in centimeters between FH and mod-
ified projected adult height) for group A (n  19), group B (n  20),
and group C (n  21), respectively.
FIG. 4. HV (A) and bone maturation (B) before and after initiation of
low dose estrogen (E2) treatment for group A (F), group B (Œ), and
group C (f) in girls who initiated estrogen treatment at age 12 yr (n
47). The black signs indicate the HV and bone maturation after ini-
tiation of estrogen treatment.
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months after discontinuation of GH treatment was not sig-
nificantly different from zero (mean IGF-I level for same age
and sex reference population) for groups B and C, but was
less than zero for group A (P  0.05).
Safety
No adverse events were detected that were considered GH
related. Treatment was well tolerated. A previously pub-
lished report using the same study group to describe glucose
tolerance during long-term GH treatment showed no ad-
verse effects on glucose levels (22). Furthermore, no signif-
icant differences in glucose and insulin levels between the
GH dosage groups during long-term GH treatment were
found (22). With the exception of two girls, glycosylated
hemoglobin levels as well as leukocytes, hemoglobin, creat-
inine, aspartate aminotransferase, alanine aminotransferate,
alkaline phosphatase, free T4, and TSH levels remained
within the normal range, and none of the children developed
diabetes mellitus. Two girls had abnormal laboratory find-
ings; one girl developed autoimmune hypothyroidism and
was treated with thyroid hormone during the study, and
another girl developed elevated levels of hepatic enzymes
and hepatomegaly resulting from hepatic glandular
malformations.
Discussion
In this paper we present FH results in 60 girls with TS after
long-term GH treatment in three dosages. We show that
when puberty is induced at a normal age, a GH dosage of 4
IU/m2d (group A) in TS leads to a mean FH of 157.6 cm,
which is equal to an sd score of 1.6 when using references
for normal Dutch girls, whereas using 6 IU/m2d (group B)
leads to a significantly higher FH of 162.9 cm (sd score,0.7).
Administration of an even higher dosage of GH (8 IU/m2d;
group C) did not lead to a significant increase in attained FH
compared with group B. As a result, 83% of the girls with TS
reached a normal FH (FH sd score above 2), and 63%
reached a FH within their target height range (TH 1.3 sd).
Our study shows that when GH was started at a mean age
of 6.6 yr, the mean gain in FH [estimated by subtracting
Lyon’s predicted adult height, adjusted for Dutch girls with
TS (mPAH), from attained FH] varied from 11.9 cm in group
A to 16.9 cm in group C. The reason why previous studies
reported a considerably lower gain in FH probably lies in the
fact that they started GH treatment at an older age (8, 23, 24).
This is confirmed by the finding that other studies, starting
GH treatment at a younger mean age, also showed a greater
gain in FH (7, 25, 26). In addition, in our study we found that
in a regression model containing HV sd score in the first year,
height sd score and age at the start of treatment, GH peak,
and GH dosage, a lower age at the start of treatment pre-
dicted a greater gain in FH. Another factor that predicted FH
gain was the dosage of GH. Our study showed that using a
dosage of 6 or 8 IU/m2d, instead of 4 IU/m2d, significantly
increased gain in FH. Using a dose of 8 IU/m2d, however,
showed no advantage over a dose of 6 IU/m2d for gain in
FH. Our results were confirmed by two nonrandomized
studies showing a dose-dependent increase in FH gain
(27, 28).
Estrogen treatment in our study was initiated from the age
of 12 yr to mimic normal pubertal development as much as
possible. The result was breast development about 2 yr later
than the 50th percentile in normal Dutch girls (13). In other
studies most girls start at a later age (23, 28); some even start
estrogen treatment at 15–16 yr (7, 25). In our opinion, how-
ever, based on our professional experience and research (29),
it is important for the psychological well-being of girls with
TS that puberty be induced at an age as close as possible to
that experienced by their peers.
In addition, we show that starting a low dose of natural
estrogen at a relatively young age did not have a negative
effect on HV or bone maturation and, therefore, possibly on
height gain. Other studies, in contrast, found a decrease in
HV and an increase in bone maturation leading to a decrease
in height gain (25, 30). The reason why our results are in
conflict with these studies, however, might be that a higher
dose of estrogen was used compared with that in our study.
Another possible explanation might be that estrogen treat-
ment was started after at least 4 yr of GH treatment. In these
4 yr, the height sd score for the whole group increased from
–2.7 at the start of GH therapy to –0.9 at the start of estrogen
treatment, showing that most of the catch-up growth had
already occurred before estrogen treatment was initiated.
Confirming this explanation, Reiter et al. (26) found that a
longer duration of estrogen-free GH treatment strongly pre-
FIG. 5. IGF-I SD score during GH treatment for group A (),
group B (u), and group C (f), respectively.
TABLE 3. Variables in prediction model for FH SD score (n  60)
Independent variable Regressioncoefficient SE P
Height SD score at starta 0.80 0.09 0.0001
Group Cb 0.81 0.18 0.0001
Group Bb 0.68 0.18 0.001
First year HVc 0.24 0.06 0.01
Age at start 0.087 0.04 0.05
Regression equation: FH SD score2.29 0.80 height SD score
at start  0.81  group C (yes  1/no  0)  0.68  group B (yes 
1/no  0)  0.24  HV in first year  0.087  CA at start.
a Using references for normal girls.
b Group C, 1  yes/0  no; group B, 1  yes/0  no.
c In first year of GH treatment (centimeters per year).
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dicted a greater gain in near FH. Our results, therefore, sug-
gest that if GH is started at a young age, FH will not be
affected by early initiation of estrogen.
When analyzing the factors most likely to influence FH sd
score, we found that a model containing the height sd score
at the start of treatment using references for normal girls, GH
dosage, first year height velocity (in centimeters), and age at
start of treatment (in years) explained 76% of the variation in
FH sd score outcome. To keep the model accessible for all
clinicians, the peak GH level during arginine tolerance test,
which is often not available in clinical practice, was not tested
as a potential predictor, and HV was expressed in centime-
ters. The model can be used to decide which dosage to use
by filling in the different variables. For example, a girl with
TS, with a height sd score at the start of GH treatment of –3,
an HV of 10 cm/yr after 1 yr of GH treatment (1 yr conven-
tional dose of 4 IU/m2d), and an age at the start of treatment
of 6 yr would attain a final height sd score of –1.5 when the
GH dose is not increased and an FH sd score of –0.8 or –0.7
when the GH dose is increased by 50% or 100%. Illustrating
the effect of height sd score at the start of treatment, in a
second example a similar girl with a height sd score at start
of –4 would attain FH sd scores of –2.6, 1.9, and –1.7,
respectively. In a third example, using the same character-
istics as in the first example, changing the HV in the first year
to 8 cm/yr would result in FH sd scores of –2.2, 1.6, and
–1.4, respectively. As a fourth and last example, when the girl
is 10 yr at the start of treatment, with a lower first year HV
of 8.5 cm/yr (mean first year HV in our study for that age,
as first year HV decreases with age), and a similar height sd
score at the start of treatment, she would attain FH sd scores
of –1.8, 1.1, and –1, respectively. Depending on one’s goal,
for instance achieving a normal FH or reaching the TH range,
the GH dosage could be adjusted accordingly. Reasons why
one might choose to increase the GH dosage are a low height
sd score at the start of treatment and/or a low HV in the first
year of treatment. Examples 2 and 3 show that these variables
might lead to a lower FH sd score when using the conven-
tional GH dose. Another reason for increasing the GH dosage
is an older age at the start of treatment, shown in a separate
correlation analysis between age at the start of treatment and
FH sd score. In the model, however, we found a positive
correlation between age at the start of treatment and FH sd
score. This finding results from the adjustment for the other
variables in the model, as both first year HV and height sd
score at the start of treatment are negatively correlated with
age at start (r  0.54 and r  0.41, respectively). In other
words, older girls, due to their age, have a lower first year
HV and height sd score at the start of treatment. Therefore,
to explore the effect of age at the start of treatment in the
model, not only age at the start of treatment, but also first
year HV and height sd score should also be taken into ac-
count. Example 4 illustrates the relationship, showing a
lower predicted FH sd score compared with the first exam-
ple. A higher GH dosage, however, leads not only to a 50–
100% increase in cost, but also to a higher IGF-I sd score, and
the long-term effects of high IGF-I levels remain to be in-
vestigated (31, 32). In addition, we emphasize that although
the model has a high prediction percentage, it does leave 24%
to be explained by unknown factors. In addition, the pre-
dicted FH sd score has a large prediction interval (residual
sd of 0.54).
In conclusion, GH treatment leads to a normalization of
FH in most girls, even when puberty is induced at a relatively
normal pubertal age. The optimal dosage to use depends on
height and age at the start of treatment, and first year HV,
although the very long-term safety of using a higher GH
dosage remains to be investigated.
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